RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTCBB: PYMX), a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced today that it has been awarded two cash grants totaling $488,958 under the U.S. Government’s Qualifying Therapeutic Discovery Project (QTDP) program. Eligibility for the grant requires that a project: have the potential to develop new treatments that address “unmet medical needs” or chronic and acute diseases; reduce long-term health care costs; or represent a significant advance in finding a cure for cancer.
